COVID-19: Are Monoclonal Antibodies What the CLL Community Has Been Waiting For?
Recorded Thursday, December 2, 2021
While vaccines may be the best solution to the COVID-19 pandemic for the majority, CLL patients need an additional solution as vaccine response is variable and often impaired. Learn about monoclonal antibodies (mAbs) directed against the virus that causes COVID-19, which may be our best answer from Dr. Shahzad Mustafa, an immunology expert, and CLL Society’s own Dr. Brian Koffman and Robyn Brumble, RN.
Co-Founder and Communications Director, CLL Society
Brian Koffman, MDCM (retired), MS Ed
Co-Founder, Executive Vice President, and Chief Medical Officer
S. Shahzad Mustafa, MD
Lead Physician – Allergy, Immunology, & Rheumatology
Rochester Regional Health
Clinical Associate Professor of Medicine
University of Rochester School of Medicine and Dentistry
Robyn Brumble, MSN, RN
Director of Scientific Affairs
CLL Society Resources
Virtual Exhibit Resources
This program was made possible by grant support from Adaptive Biotechnologies, Bristol Myers Squibb, Pharmacyclics, Janssen, and Regeneron.